Formulation and Optimization of Raft Forming Chewable Tablet Containing Lafutidine

Abstract

A novel histamine H2-receptor antagonist, lafutidine has a duration of action of 1.92 hours in the body.
Because it is absorbed selectively from the upper section of the GI tract, the goal of using gastroretentive
medication administration is to increase its bioavailability. The study's overarching objective was to develop
lafutidine chewable tablets that also included an antacid, raft-forming agent, and gas-generating agent. In
vitro drug release, weight variation, acid neutralization capability, raft strength, and percentage of drug
content were some of the metrics used to assess the tablet formulation process that used the wet granulation
technique. In the first round of testing, a number of raft-forming chemicals were used. The optimization
strategy used in this work was a 32 complete factorial design. We used raft strength and acid neutralization
capability as our dependent factors, and we employed sodium alginate to pectin ratio and calcium carbonate
amount as our independent variables. Batch F8 was chosen as the optimal formulation because of its high
acid neutralization capability and highest raft strength. There was no evidence of drug-excipient interactions
in the research of drug-excipient compatibility. Optimal formulation stability testing revealed that, even
under accelerated environmental conditions, tablets remained unchanged for a full month. An effective
dosage form for the treatment of gastroesophageal reflux disease may be raft-forming chewable tablets made
with the optimal amounts of sodium alginate, pectin, and calcium carbonate